Construction of a Vibrio cholerae prototype vaccine strain O395-N1-E1 which accumulates cell-associated cholera toxin B subunit

Vaccine

Volumn 26, Issue 43, 2008, Pages 5443-5448

  Rhie, Gi eun ^a   Jung, Hae Mi ^a   Kim, Bong Su ^a   Mekalanos, John J ^b  

^a Korea National Institute of Health   (South Korea)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cholera toxin B subunit; Cholera vaccine; Vibrio cholerae

Indexed keywords

CHOLERA TOXIN B SUBUNIT; CHOLERA VACCINE; IMMUNOGLOBULIN G; INACTIVATED VACCINE; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BIOACCUMULATION; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE DISRUPTION; GENETIC ENGINEERING; IMMUNE RESPONSE; INFECTION RESISTANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; VIBRIO CHOLERAE; VIBRIO CHOLERAE 0395 N1 E1;

ANIMALS; CHOLERA TOXIN; CHOLERA VACCINES; DNA, BACTERIAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOGLOBULIN G; MICE; MICE, INBRED ICR; MUTATION; PLASMIDS; VIBRIO CHOLERAE;

EID: 52149096926     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.05.088     Document Type: Article

References (42)

1. Faruque S.M., Albert M.J., and Mekalanos J.J. Epidemiology, genetics and ecology of toxigenic Vibrio cholerae. Microbiol Mol Biol Rev 62 (1998) 1301-1314
2. Spangler B.D. Structure and function of cholera toxin and the related Escherichia coli heat-liable enterotoxin. Microbiol Rev 56 (1992) 622-647
3. Faruque S.M., Tam V.C., Chowdhury N., Diraphat P., Dziejman M., Heidelberg J.F., et al. Genomic analysis of the Mozambique strain of Vibrio cholerae O1 reveals the origin of El Tor strains carrying classical CTX prophage. Proc Natl Acad Sci 104 (2007) 5151-5156
4. Sandkvist M. Biology of type II secretion. Mol Microbiol 40 (2001) 271-283
5. Sandkvist M., Michel L.O., Hough L.P., Morales V.M., Bagdasarian M., Koomey M., et al. General secretion pathway (eps) genes required for toxin secretion and outer membrane biogenesis in Vibrio cholerae. J Bacteriol 179 (1997) 6994-7003
6. Camberg J.L., and Sandkvist M. Molecular analysis of the Vibrio cholerae type II secretion ATPase EpsE. J Bacteriol 187 (2005) 249-256
7. Robien M.A., Krumm B.E., Sandkvist M., and Ho W.G. Crystal structure of the extracellular protein secretion NTPase EPSE of Vibrio cholerae. J Mol Biol 333 (2003) 657-674
8. Overbye L.J., Sandkvist M., and Bagdasarian M. Genes required for extracellular secretion of enterotoxin are clustered in Vibrio cholerae. Gene 132 (1993) 101-106
9. Sandkvist M., Overbye L.J., Sixma T.K., Hol W.G.J., and Bagdasarian M. Assembly of Escherichia coli heat-labile enterotoxin and its secretion from Vibrio cholerae. In: Kado C. (Ed). Molecular mechanisms of bacterial virulence (1993), Kluwer Academic Publishers, Dordrecht, The Netherlands 293-310
10. Sandkvist M., Bagdasarian M., Howard S.P., and Dirita V.J. Interaction between the autokinase EpsE and EpsL in the cytoplasmic membrane is required for extracellular secretion in Vibrio cholerae. EMBO 14 (1995) 1664-1673
11. Clemens J.D., Sack D.A., Harris J.R., Chakraborty J., Khan M.R., Stanton B.F., et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 2 (1986) 124-127
12. Clemens J.D., Sack D.A., Harris J.R., Van Loon F., Chakraborty J., Ahmed F., et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 335 (1990) 270-273
13. Holmgren J., Osek J., and Svennerholm A.M. Protective oral cholera vaccine based on a combination of cholera toxin B subunit and inactivated Cholera Vibrios. In: Wachsmuth I.K., Blake P.A., and Olsvik Ø. (Eds). Vibrio cholerae and cholera: molecular to global perspectives (1994), ASM Press, Washington, DC 415-424
14. Loon F.P.V., Clemens J.D., Chakraborty J., Rao M.R., Kay B.A., Sack D.A., et al. Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. Vaccine 14 (1996) 162-166
15. Anh D.D., Canh D.G., Lopez A.L., Thiem V.D., Long P.T., Son N.H., et al. Safety and immunogenicity of a reformulated Vietnamese bivalent killed, whole-cell, oral cholera vaccine in adults. Vaccine 25 (2007) 1149-1155
16. Naficy A.B., Trach D.D., Ke N.T., Chuc N.T., Sorkin A., Rao M.R., et al. Cost of immunization with a locally produced, oral cholera vaccine in Viet Nam. Vaccine 19 (2001) 3720-3725
17. Thiem V.D., Deen J.L., von Seidlein L., Canh D.G., Anh D.D., Park J.K., et al. Long-term effectiveness against cholera of oral killed whole-cell vaccine produced in Vietnam. Vaccine 24 (2006) 4297-4303
18. Trach D.D., Clemens J.D., Ke N.T., Thuy H.T., Son N.D., Canh D.G., et al. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 349 (1997) 231-235
19. Holmgren J., Adamsson J., Anjuere F., Clemens J., Czerkinsky C., Eriksson K., et al. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA. Immunol Lett 97 (2005) 181-188
20. Ryan E.T., Butterton J.R., Zhang T., Baker M.A., Stanley S.L., and Calderwood S.B. Oral immunization with attenuated vaccine strains of Vibrio cholerae expressing a dodecapeptide repeat of the serine-rich Entamoeba histolytica protein fused to the cholera toxin B subunit induces systemic and mucosal antiamebic and anti-V. cholerae antibody response in mice. Infect Immun 65 (1997) 3118-3125
21. McKenzie S.J., and Halsey J.F. Cholera toxin B subunit as a carrier protein to stimulate a mucosal immune response. J Immunol 133 (1984) 1818-1824
22. Taylor R.K., Kirn T.J., Bose N., Stonehouse E., Tripathi S.A., Kovac P., et al. Progress towards development of a cholera subunit vaccine. Chem Biodivers 1 (2004) 1036-1057
23. Taylor R.K., Miller V.L., Furlong D.B., and Mekalanos J.J. Use of phoA gene fusions to identify a pilus colonization factor regulated coordinately with cholera toxin. Proc Natl Acad Sci 84 (1987) 2833-2837
24. Levine M.M., Kaper J.B., Herrington D., Losonsky G., Morris J.G., Clements M.L., et al. Volunteer studies of deletion mutants of Vibrio cholerae O1 prepared by recombinant techniques. Infect Immun 56 (1988) 161-167
25. Mekalanos J.J., Swartz D.J., Pearson G.D., Harford N., Groyne F., and deWilde M. Cholera toxin genes: nucleotide sequence, deletion analysis and vaccine development. Nature 306 (1983) 551-557
26. Coster T.S., Killeen K.P., Waldor M.K., Beattie D.T., Spriggs D.R., Kenner J.R., et al. Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype. Lancet 345 (1995) 949-952
27. Herrington D.A., Hall R.H., Losonsky G., Mekalanos J.J., Taylor R.K., and Levine M.M. Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med 168 (1988) 1487-1492
28. Qadri F., et al. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. J Infect Dis 192 (2005) 573-579
29. Qadri F., et al. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine 25 (2007) 231-238
30. In: Ausbel F.M., Brent R., Kingston R.E., Moore D.E., Seidman J.G., Smith J.A., et al. (Eds). Current protocols in molecular biology (1995), Wiley, New York
31. Datsenko K.A., and Wanner B.L. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci 97 (2000) 6640-6645
32. Metcalf W.W., Jiang W., Daniels L.L., Kim S.K., Haldimann A., and Wanner B.L. Conditionally replicative and conjugative plasmids carrying lacZα for cloning, mutagenesis, and allele replacement in bacteria. Plasmids 35 (1996) 1-13
33. Simon R., Priefer U.B., and Puhler A. A broad host range mobilization system for in vivo genetic engineering: transposon mutagenesis in gram-negative bacteria. Bio/Technology 1 (1983) 784-791
34. Gardel C.L., and Mekalanos J.J. Regulation of cholera toxin by temperature, pH, and osmolarity. Methods Enzymol 235 (1994) 517-526
35. Holmes R.K., Vasil M.L., and Finkelstein R.A. Studies on toxinogenesis in Vibrio cholerae. III. Characterization of nontoxigenic mutants in vitro and in experimental animals. J Clin Invest 55 (1975) 551-560
36. Ali A., Johnson J.A., Franco A.A., Metzger D.J., Connell T.D., Morris Jr. J.G., et al. Mutations in the extracellular protein secretion pathway genes (eps) interfere with rugose polysaccharide production in and motility of Vibrio cholerae. Infect Immun 68 (2000) 1967-1974 [erratum in: Infect. Immun. 68: 3792]
37. Davis B.M., Lawson E.H., Sandkvist M., Ali A., Sozhamannan S., and Waldor M.K. Convergence of the secretory pathway for cholera toxin and the filamentous phage, CTXΦ. Science 288 (2000) 333-335
38. Chiang S.L., and Mekalanos J.J. Construction of a Vibrio cholerae vaccine candidate using transposon delivery and FLP recombinase-mediated excision. Infect Immun 68 (2000) 6391-6397
39. Kenner J.R., Coster T.S., Taylor D.N., Trofa A.F., Barrera-Oro M., Hyman T., et al. Peru-15, an improved live attenuated oral vaccine candidate for Vibrio cholerae O1. J Infect Dis 172 (1995) 1126-1129
40. Tacket C.O., Losonsky G., Nataro J.P., Cryz S.J., Edelman R., Fasano A., et al. Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae. J Infect Dis 168 (1993) 1536-1540
41. Neutra M.R. M cells in antigen sampling in mucosal tissues. Curr Top Microbiol Immunol 236 (1999) 17-32
42. Butterton J.R., Beattie D.T., Gardel C.L., Carroll P.A., Hyman T., Killeen K.P., et al. Heterologous antigen expression in Vibrio cholerae vector strains. Infect Immun 63 (1995) 2689-2696